Patents Assigned to Cedars-Sinai Medical Center
  • Publication number: 20190178890
    Abstract: The present invention describes methods for preventing IBS, reducing the likelihood of developing IBS and/or treating IBS by administering CDT inhibitors and/or CDT neutralizers to a subject in need thereof. The present invention also describes methods of eliciting a specific immune response and methods of vaccinating a subject to prevent IBS or to reduce the likelihood of developing or having IBS. The present invention further describes methods of diagnosing IBS by detecting the presence or absence of CDT or a CDT marker in a subject.
    Type: Application
    Filed: November 9, 2018
    Publication date: June 13, 2019
    Applicant: Cedars-Sinai Medical Center
    Inventors: Mark Pimentel, Christopher Chang
  • Publication number: 20190175938
    Abstract: The disclosed technology relates to a system for delivering UV-A/B light with a catheter to treat infectious or inflammatory disorders in a patient. While UV light in the UV-C range has traditionally been used to treat skin disorders and for focused ablation of plaques in the arteries and other targeted internal uses, it has not been developed for broader infection, inflammation or neoplasia treatment inside the human body.
    Type: Application
    Filed: May 31, 2017
    Publication date: June 13, 2019
    Applicant: Cedars-Sinai Medical Center
    Inventors: Ali REZAIE, Mark PIMENTEL, Gil Y. MELMED
  • Patent number: 10316083
    Abstract: The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL17 secretion from TH17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: June 11, 2019
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Kathrin S. Michelsen, Stephan R. Targan
  • Patent number: 10309974
    Abstract: Disclosed herein are methods for diagnosing cardiovascular disease. The methods comprise detection of citrullinated proteins and/or citrullinated peptides. Also disclosed herein are methods, compositions, and kits for diagnosing and/or treating cardiovascular disease.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: June 4, 2019
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Justyna P. Fert-Bober, Jennifer E. Van Eyk
  • Publication number: 20190160111
    Abstract: Described herein are compositions and methods related to use of exosomes, including cardiosphere derived cell (CDC)-derived exosomes for treatment and prevention of heart related disease and conditions, such as ventral arrhythmias, such as tachycardias. CDC-derived exosomes delivered by endocardial injection can diminish the total amount of isolated late potentials associated with an isthmus of slow conduction, while reducing the isoelectric interval between late abnormal ventricular activity and decreasing the incidence of inducible ventricular arrhythmias, thereby providing a biological treatment for arrhythmias which otherwise requires therapeutic interventions with adverse effects.
    Type: Application
    Filed: June 2, 2017
    Publication date: May 30, 2019
    Applicant: Cedars-Sinai Medical Center
    Inventors: Eduardo Marban, Eugenio Cingolani, James Dawkins
  • Publication number: 20190153395
    Abstract: Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.
    Type: Application
    Filed: February 1, 2017
    Publication date: May 23, 2019
    Applicant: Cedars-Sinai Medical Center
    Inventors: Robert Barrett, Clive Svendsen, Stephan R. Targan, Michael Workman, Dhruv Sareen, Uthra Rajamani
  • Publication number: 20190142895
    Abstract: The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.
    Type: Application
    Filed: January 17, 2019
    Publication date: May 16, 2019
    Applicant: Cedars-Sinai Medical Center
    Inventors: Mark Pimentel, Ruchi Mathur, Christopher Chang
  • Patent number: 10288567
    Abstract: The invention provides systems for characterizing a biological sample by analyzing emission of fluorescent light from the biological sample upon excitation and methods for using the same. The system includes a laser source, collection fibers, a demultiplexer and an optical delay device. All references cited herein are incorporated by reference in their entirety as though fully set forth. Unless defined otherwise, technical and scientific tens used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: May 14, 2019
    Assignee: Cedars-Sinai Medical Center
    Inventors: Pramod Butte, Paul Lapchak, David Scott Kittle
  • Publication number: 20190136203
    Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.
    Type: Application
    Filed: January 14, 2019
    Publication date: May 9, 2019
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
  • Publication number: 20190136286
    Abstract: Disclosed are methods of diagnosing constipation and constipation-predominant irritable bowel syndrome by screening for the presence of abnormally high levels of methane and/or methanogenic organisms in a subject.
    Type: Application
    Filed: August 2, 2018
    Publication date: May 9, 2019
    Applicant: Cedars-Sinai Medical Center
    Inventors: Mark Pimentel, Henry C. Lin
  • Publication number: 20190117145
    Abstract: Disclosed herein is a rodent and human behavioral test for evaluating visual dysfunctions associated with the retinal changes in Alzheimer disease progression. In one example, the inventors developed a maze that tests rodent's ability to identify (1) specific contrasts, (2) specific colors, (3) certain items in the visual field, and (4) other ‘non-typical’ peripheral and night vision functions associated with AD. For instance, the inventors developed a maze the tests the rodents ability to avoid certain colors or contrasts gradients. The maze may include certain rooms with specific visual markers (e.g., colors, contrasts, objects or other visual features) that also contain shock plates.
    Type: Application
    Filed: June 2, 2017
    Publication date: April 25, 2019
    Applicant: Cedars-Sinai Medical Center
    Inventors: Maya KORONYO, Yosef KORONYO, Keith L. BLACK
  • Publication number: 20190117729
    Abstract: The present invention describes methods of treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of a medical condition related to ischemia/reperfusion in a subject using GJA1-20k as a therapeutic agent. The invention further provides a method of protecting a cell from metabolic stress, using GJA1-20k. The invention also provides for a composition and/or gene expression vector comprising GJA1-20k.
    Type: Application
    Filed: April 13, 2017
    Publication date: April 25, 2019
    Applicant: Cedars-Sinai Medical Center
    Inventors: Robin Shaw, TingTing Hong, Ying Fu, Shaohua Xiao, Wassim Basheer
  • Patent number: 10266505
    Abstract: The invention describes compounds that inhibit both HDAC and GSK3? (i.e., HDAC/GSK3? dual inhibitors). The invention further describes compositions containing these HDAC/GSK3? dual inhibitors, as well as methods and kits using these HDAC/GSK3? dual inhibitors to treat various medical conditions. The invention also provides methods and kits using a HDAC inhibitor and a GSK3? to treat various medical conditions, and compositions containing a HDAC inhibitor and a GSK3?. Medical conditions treatable with various embodiments of the invention include but are not limited to cancers and tumors.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: April 23, 2019
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Mouad Edderkaoui, Ramachandran Murali, Stephen Pandol
  • Patent number: 10253368
    Abstract: Described herein are gene signatures providing prognostic, diagnostic, treatment and molecular subtype classifications of ovarian cancers through generation of ovarian cancer disease signatures (OCDSs) that account for molecular heterogeneity present in gynecological cancers. An ovarian cancer fixed signature (OCFS) is described which relates to the core programming of disease development, in addition to an ovarian cancer stem cell (OCSC) signature. Development various disease signature, suggests personalized treatment strategies focused on molecular subtypes of gynecological cancers, such as triage tests for patients.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: April 9, 2019
    Assignee: Cedars-Sinai Medical Center
    Inventors: Sandra Orsulic, Beth Y. Karlan, Xiaojiang Cui, Mourad Tighiouart, Dong-Joo Cheon, Zhenqiu Liu
  • Patent number: 10254285
    Abstract: The invention provides methods for isolating large oncosomes and determining cancer metastasis based on the presence of large oncosomes and contents of the large oncosomes in a subject in need thereof. Also provided herein are methods for treating cancer metastasis by specifically targeting contents of the large oncosomes.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: April 9, 2019
    Assignee: Cedars-Sinai Medical Center
    Inventors: Dolores Di Vizio, Michael R. Freeman, Matteo Morello, Valentina R. Minciacchi
  • Patent number: 10245298
    Abstract: The invention provides methods for treating fibrosis and/or cancer in a subject in need thereof. The methods include providing a composition comprising an inhibitor of IL-4/IL-13 receptor function and administering an effective amount of the composition to the subject to treat fibrosis and/or cancer.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: April 2, 2019
    Assignees: Cedars-Sinai Medical Center, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ramachandran Murali, Aida Habtezion, Stephen J. Pandol
  • Publication number: 20190083231
    Abstract: Tendon and ligament injuries are common in orthopaedic clinical practice and cause substantial morbidity in sports and in routine daily activities. While surgical reconstruction is effective, the majority of patients suffer from a prolonged period of recovery because of limited regeneration capacity of the tendon-bone interface. Here, the Inventors have established an approach for promoting tendon/ligament integration. By first recruiting endogenous stem cells to the site of injury, bone morphogenic proteins (BMPs), are then delivered in vivo to promote repair. Significant acceleration of healing via the above methods and compositions leads to fast recovery and return to normal activities, thereby providing new therapeutic avenues for treatment of injuries involving the tendon-bone interface.
    Type: Application
    Filed: February 28, 2017
    Publication date: March 21, 2019
    Applicant: Cedars-Sinai Medical Center
    Inventors: Dan Gazit, Gadi Pelled, Thomas Kremen
  • Publication number: 20190083507
    Abstract: The present disclosure teaches methods for treating and preventing a variety of neurodegenerative conditions and symptoms associated therewith, including Alzheimer's disease (AD) and idiopathic Parkinson's disease (iPD), by utilizing adrenoceptor antagonists. Adrenoceptor antagonists that can be used include ?-blockers, such as acebutolol, betaxolol, bisopropolol, bopindolol, carvedilol, metoprolol, oxprenolol, propranolol, and timolol. The present disclosure also teaches methods for diagnosing and monitoring the progression of iPD.
    Type: Application
    Filed: September 26, 2018
    Publication date: March 21, 2019
    Applicant: Cedars-Sinai Medical Center
    Inventors: Michele Tagliati, Gennaro Pagano
  • Publication number: 20190076555
    Abstract: Imaging nanoagents including a polymalic acid-based molecular scaffold, a chlorotoxin peptide or a variant thereof, and at least one fluorescent moiety are provided. Methods for detecting, treating and removing a cancer in a subject by administering the imaging nanoagent are described.
    Type: Application
    Filed: September 12, 2018
    Publication date: March 14, 2019
    Applicant: Cedars-Sinai Medical Center
    Inventors: Rameshwar Patil, Eggehard Holler, Julia Y. Ljubimova, Adam Mamelak, Keith L. Black
  • Patent number: 10226519
    Abstract: Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: March 12, 2019
    Assignee: Cedars-Sinai Medical Center
    Inventors: John S. Yu, Gentao Liu, Keith L. Black